Stay updated with breaking news from Davids Rubenstein. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Seven posters will include clinical data for VTAMA cream for the treatment of plaque psoriasis in adults and atopic dermatitis (AD), including data from the successful pediatric maximum usage study
- Five posters will highlight clinical data for VTAMA cream for the treatment of plaque psoriasis in adults and for atopic dermatitis in patients as young as two - Dermavant Sciences, a biopharmaceutical
- Two posters will present data across secondary efficacy outcomes, quality of life and tolerability scores of tapinarof cream 1% once daily - Dermavant Sciences, a clinical-stage biopharmaceutical
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/5SKMVSZ7LRGPJLOILRQLH43K5U.jpg)
“Los funcionarios de salud pública van a tener que decidir si todos deben recibir una vacuna de refuerzo”, dijo Noubar Afeyan.
Dermavant Sciences: Dermavant Announces Tapinarof Data Presentations at the AAD VMX 2021 Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that two abstracts from Dermavant's two pivotal Phase 3 trials for tapinarof for the treatment of psoriasis in adults, PSOARING 1 and PSOARING 2, will be presented during the upcoming American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX 2021), on April 23-25, 2021. Tapinarof is being developed as a novel, once-daily th...